Clinical Trial Update: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 [Phase 2, Phase 3]

View source ↗

Summary

Ongoing Phase 2 and Phase 3 trials from Mirati evaluate adagrasib as a standalone therapy and in combination with pembrolizumab for KRAS G12C-mutant advanced/me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adagrasib (adagrasib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING